Novavax, Inc. Stock News

GAITHERSBURG, Md. , Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adjuvant.

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.

Novavax, Inc. (NASDAQ:NVAX ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:20 AM EDT Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Pete Stavropoulos - Cantor Presentation Pete Stavropoulos Welcome to the Cantor Global Hea...

GAITHERSBURG, Md. , Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine Nuvaxovid® Intramuscular Injection 1 mL formulated to target SARS-CoV-2 Omicron LP.8.1 as an initial immunization (first and second vaccination) for those aged six years or older and a booster imm...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season GAITHERSBURG, Md. , Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026 Formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years throug...

Refinancing extends maturity of most existing debt with improved terms $225 million of convertible notes due in 2031 issued, including a ~$175 million exchange for the retirement of existing convertible notes due in 2027 and ~$50 million of new money GAITHERSBURG, Md. , Aug. 21, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has entered into privately negotiated agree...

Novavax (NVAX) Profit Jumps on Milestone

Novavax, Inc. (NASDAQ:NVAX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & Director Luis Sanay - Corporate Participant Ruxandra Draghia-Akli - Executive VP and Head of Research & Development Silvia Taylor - Corporate Participant Conference Call Participants Alec Warren St...